

선천성 QT 연장 증후군의 임상적 특성에 대한 고찰

김정호¹ · 남기병¹ · 김현국¹ · 이경석¹ · 한기훈¹
 최기준¹ · 고재곤² · 박인숙² · 김유호¹

Clinical and Electrocardiographic Features of Patients with Congenital Long QT Syndrome

Jung-Ho Kim, MD¹, Gi-Byoung Nam, MD¹, Hyun Kuk Kim, MD¹,
 Kyoung-Suk Rhee, MD¹, Ki Hoon Han, MD¹, Kee-Joon Choi, MD¹,
 Jae Kon Ko, MD², In-Sook Park, MD² and You-Ho Kim, MD¹

¹Department of Internal Medicine, ²Pediatrics, Ulsan University College of Medicine, Asan Medical Center, Seoul, Korea

ABSTRACT

Background and Objectives : Congenital long QT syndrome (LQTS) is characterized by the prolongation of the QT interval, frequent episodes of syncope and Torsades de Pointes (TdP). The clinical features and electrocardiographic findings in Korean patients with LQTS have not been reported. **Subjects and Methods** : We retrospectively analyzed the clinical characteristics, ECG features and response to treatments in 11 patients (6 men, 5 women) with congenital LQTS. **Results** : The mean age at the time of the first episode was 19.4 ± 22.6 years old (range : 1 - 70 years). Clinical presentations were syncope, seizure or sudden cardiac death (SCD). Predisposing factors included exercise, sudden startle or sleep. Only three patients showed familial histories of syncope or SCD. The average QTc interval was 0.58 ± 0.05 second (range : 0.47 - 0.61 seconds). T wave morphologies were classified as normal-appearing, broad-based, low amplitude/bifid or late onset. For its management, bblockers were used in 7 patients. In 2 patients, whose clinical events were related with to an increased vagal tone or were aggravated by blocker therapy, mexiletine was prescribed. When bradycardia or AV block was documented, pacemakers were implanted. For 2 patients at high risk of sudden cardiac death, cardioverter-defibrillators were implanted. During a mean follow up period of 23.5 ± 20.2 months (range : 3 - 64 months), symptoms (cardiac arrest) recurred in 1 patient. **Conclusion** : Congenital LQTS is a heterogeneous disease, showing diverse clinical manifestations, ECG features, and response to pharmacological management. Further research on the genotype-phenotype relationship will refine the management, enabling gene-specific treatment of this life-threatening disease. (**Korean Circulation J 2002;32 (9):798-806**)

KEY WORDS : Long QT syndrome ; Electrocardiography ; Death, sudden ; Syncope ; Arrhythmia.

: 2002 7 23
 : 2002 8 20
 : , 138 - 736 388 - 1
 : (02) 3010 - 3161 · : (02) 486 - 5918 · E - mail : youho@www.amc.seoul.kr

서론

QT (The Long QT Syndrome ; LQTS) QT (1-3) , sympathetic imbalance theory가 , genotype - phenotype (1)2)4) 11 LQTS 11 ±22.6 (1 70) (aborted cardiac arrest) 5 (1, 2, 4, 8, 11) 3 (5, 7, 10) 3 (3, 6, 9) 11 LQTS 3

대상 및 방법

1991 1 2002 5 9) 11 LQTS 3

결과

임상적 특성 (Table 1)

가 6 , 가 5 19.4

Table 1. Clinical characteristics of the study patients

No	Sex/age	FHx	Provocating factor	Structural heart ds	Clinical manifestation
1	M/21	+	Isometric exercise	-	Palpitation, syncope, TdP (+)
2	F/43	-	Sudden startle	-	Palpitation, syncope, TdP (+)
3	F/42	-	Sleeping (resting)	-	Aborted cardiac arrest
4	M/8	-	Isotonic exercise	-	Syncope
5	M/3	-	Non-specific	-	Seizure, deafness (both)
6	F/4	-	Non-specific	-	Aborted cardiac arrest TdP (+), CAVB
7	M/3	-	Sleeping	Small VSD	Seizure
8	M/12	+	Isotonic exercise	-	Syncope
9	F/6	-	Non-specific	-	Aborted cardiac arrest
10	M/1	-	Non-specific	-	Seizure
11	F/70	+	Non-specific	-	Palpitation, syncope, TdP (+)

TdP : torsades de pointes, LOC : loss of consciousness, CAVB : complete atrioventricular block ICD : implantable cardioverter/defibrillator, FHx : familiar history, VSD : ventricular septal defect




Fig. 1. Induction of TdP during exercise provocation test. TdP was induced by isometric exercise test (chest pressor) in patient 1. Tachycardia was not induced after repeated attempts of isotonic treadmill exercise test, while being induced reproducibly by chest pressor. This suggests that tachycardia induction in congenital long QT syndrome is dependent on the type of exercise. TdP : torsades de pointes.

3
(generalized seizure)
가
가 3 (1, 4, 8),
가 1 (2)
가 2 (3, 7)
5 (5, 6, 9, 10, 11)
3 (1, 4, 8) 1 (iso-
metric exercise)
4 8
가
(isotonic exercise)
2
1
3
QT 7 T
(tonic seizure)
가 3 (1, 8, 11) 27 %
1 3
(23) (24)
8 가
11
가
5

Table 2. ECG characteristics

No	QT/QTc	T wave pattern
1	0.66/0.60	Normal appearing T wave T wave inversion (V1 -4)
2	0.64/0.59	Bifid T wave
3	0.38/0.55	Late onset T wave T wave alternans (+)
4	0.47/0.54	Broad based T wave
5	0.52/0.65	Broad based T wave
6	0.52/0.58	Normal appearing T wave
7	0.60/0.60	Broad based or biphasic T Wave
8	0.37/0.47	Broad based T wave T wave alternans (+)
9	0.55/0.66	Normal appearing T wave T wave inversion (V1 -4)
10	0.47/0.57	Normal appearing T wave Pseudo 2 : 1 AV block
11	0.53/0.53	Low amplitude T wave

AV block : atrioventricular block

가
검사 소견
(treadmill test), 24 (Holter monitoring),
1 (7)
4 (1, 2, 4, 9) 1
chest pressor (Fig. T
1), 24
(T wave alternans)
3 (1, 2, 11)

심전도상의 특징 (Table 2)

QTc 0.58 ± 0.05
 (: 0.47 0.66)

ST - T

Moss ⁶⁾ Zhang ⁷⁾

4 (1, 6, 9, 10) broad-based T

4 (4, 5, 7, 8) low ampli-

tude bifid T 2 (2, 11)

1 (3) late onset T (Fig.

2). 3 (1, 3, 8) T

(Fig. 3), 1 (10) pseudo 2 : 1

AV block (Fig. 4).

치료 및 추적 관찰 기간 (Table 3)

(

1, 2, 8) (5, 6,




Fig. 2. Different patterns of ST-T wave complex in patients with long QT syndrome. A : normal-appearing T wave pattern (patient 1), B : broad-based T wave pattern (patient 5), C : low-amplitude bifid T wave pattern (patient 2), D : late onset T wave (patient 3).




Fig. 3. T wave alternans. Alternation of the T wave amplitude and polarity was recorded during Holter monitoring (patient 8).




Fig. 4. First degree or 2 : 1 pseudo AV block. Functional AV block occurred in the setting of fast atrial rate and dramatically prolonged ventricular repolarization as the P waves fell within the T wave (Patient 10).

Table 3. Treatment and follow-up periods

No	Treatment	Follow-up periods (month)				
1	blocker, ICD	12	1 (10)			
2	blocker, ICD	29	1 (4)			
3	Isoproterenol, mexiletine	26		1 (4)	10	
4	None	F/U loss		23.5±20.2	(: 3 64	
5	blocker, ICD (refused)	5)	1 (9)		
6	blocker, pacemaker	64		가		
7	Mexiletine, pacemaker	5				
8	blocker	3				
9	blocker, ICD (refused)	38				
10	Observation	10				
11	blocker	43				

ICD : implantable cardioverter/defibrillator

9, 11) 7
 TdP 가 1)3)8
 2 (1, 2)
 (implantable cardioverter/defibrillator : ICD) 가 , LQTS 가
 11 가 LQTS 가
 amiodarone TdP amioda- 1)
 rone 가 1
 (6)
 (cardiac pacemaker) 가 QT
 7

¹⁾¹³⁾¹⁴⁾ LQTS2 LQTS6 HE-
 RG, MiRP1(KCNE2) ¹⁾ rapidly
 activating delayed rectifier K (I_{Kr})

¹⁾¹⁵⁾ LQTS3
 (SCN5A)

¹⁾¹⁶⁾¹⁷⁾ LQTS4
 (chromosomal locus ; 4q25 - 27)

¹⁾¹⁸⁾ JLN
 2가 JLN1 JLN2
 KVLQT1(KCNQ1), minK(KCNE1)
 slowly activating delayed rectif-
 ier K (I_{Ks})

¹⁾¹⁹⁾ LQTS
 3가 (LQTS 1, 2, 3)

¹⁾³⁾ LQTS1 : 45.5%,
 LQTS2 : 29.3%, LQTS3 : 25.5% LQTS1
 가 가 ³⁾²⁰⁾

¹⁾²⁾ LQTS1 ()
 (,)
 TdP

T broad-based T T

²⁾¹¹⁾ LQTS 30 50%
 Moss ²²⁾ 가
 14% 5

LQTS Romano - Ward(RW) Jervell - Lange - Nielsen LQ-
 (JLN) RW 5가
 TS , JLN 2가 가 ¹⁾ RW
 5가 LQTS1 LQTS5
 KVLQT1(KCNQ1), minK(KCNE1)
 , slowly activating delayed rectifier K
 (I_{Ks})

ICD ¹⁾²⁾²²⁾
 LQTS2 (,)
) T low
 amplitude bifid T
 가
 LQTS3

broad based T
, mexiletine
5
JLN
(homozygote)
2)30)
ICD
LQTS
LQTS1
6 (1, 4, 6, 8, 9, 10), LQTS2가 2 (2,
11), LQTS3 1 (3)
5) Jervell - Lange - Nielsen

19.4 ± 22.6 (1 70)
가
3
QTc 0.58 ± 0.05 (: 0.47 0.66)
, T , broad - based T , low
amplitude/bifid T , late onset T
7
2
mexiletine
(ICD)
23.5 ± 20.2 (: 3 64)
() 1

결 론

결 론 :

LQTS , , genotype - phenotype , 가 가

LQTS , , 중심 단어 : QT ; ; ; ;

요 약

REFERENCES

배경 및 목적 :
QT (the long QT syndrome, LQ-
TS) QT
방 법 :
1991 1 2002 5
11 LQTS
결 과 :
11 가 6 , 가 5

- 1) Chiang CE, Roden DM. *The long QT syndrome: genetic basis and clinical implications. J Am Coll Cardiol* 2000;36:1-12.
- 2) Viskin S. *Long QT syndromes and torsade de pointes. Lancet* 1999;354:1625-33.
- 3) Passman R, Kadish A. *Polymorphic ventricular tachycardia, long QT syndrome, and torsades de pointes. Med Clin North Am* 2001;85:321-41.
- 4) Schwartz PJ, Priori SG, Spazzolini C, Moss AJ, Vincent GM, Napolitano C, Denjoy I, Guicheney P, Breithardt G, Keating MT, Towbin JA, Beggs AH, Brink P, Wilde AA, Toivonen L, Zareba W, Robinson JL, Timothy KW, Corfield V, Wattanasirichaigoon D, Corbett C, Haverkamp W, Schulze-Bahr E, Lehmann MH, Schwartz K, Coumel P, Bloise R. *Genotype-phenotype correlation in the long-QT syndrome: genespecific triggers for life-threatening arrhythmias. Circulation* 2001;103:89-95.
- 5) Schwartz PJ, Moss AJ, Vincent GM, Crampton RS. *Diagnostic criteria for the long QT syndrome: an update. Circulation* 1993;88:782-4.
- 6) Moss AJ, Zareba W, Benhorin J, Locati EH, Hall WJ, Robinson JL, Schwartz PJ, Towbin JA, Vincent GM, Lehmann MH. *ECG T-wave patterns in genetically distinct forms of the hereditary long QT syndrome. Circulation* 1995;92:2929-34.
- 7) Zhang L, Timothy KW, Vincent GM, Lehmann MH, Fox J, Giuli LC, Shen J, Splawski I, Priori SG, Compton SJ, Yanco-

- witz F, Benhorin J, Moss AJ, Schwartz PJ, Robinson JL, Wang Q, Zareba W, Keating MT, Towbin JA, Napolitano C, Medina A. *Spectrum of ST-T-wave patterns and repolarization parameters in congenital long QT syndrome: ECG findings identify genotypes. Circulation 2000;102:2849-55.*
- 8) Vincent GM, Timothy KW, Leppert M, Keating M. *The spectrum of symptoms and QT intervals in carriers of the gene for the long QT syndrome. N Engl J Med 1992;327:846-52.*
 - 9) Dillenburg RF, Hamilton RM. *Is Exercise testing useful in identifying congenital long QT syndrome? Am J Cardiol 2002; 89:233-6.*
 - 10) Swan H, Toivonen L, Viitasalo M. *Rate adaptation of QT intervals during and after exercise in children with congenital long QT syndrome. Eur Heart J 1998;19:508-13.*
 - 11) Vincent GM. *Role of DNA testing for diagnosis, management, and genetic screening in long QT syndrome, hypertrophic cardiomyopathy, and Marfan syndrome. Heart 2001;86:12-4.*
 - 12) Viskin S, Belhassen B. *Polymorphic ventricular tachyarrhythmias in the absence of organic heart disease: classification, differential diagnosis and implications for therapy. Prog Cardiovasc Dis 1998;41:17-34.*
 - 13) Sanguinetti MC, Curran ME, Zou A, Shen J, Spector PS, Atkinson DL, Keating MT. *Coassembly of K (V) LQT1 and minK (IsK) proteins to form cardiac I (Ks) potassium channel. Nature 1996;384:80-3.*
 - 14) Barhanin J, Lesage F, Guillemare E, Fink M, Lazdunski M, Romey G. *K (V) LQT1 and IsK (minK) proteins associate to form the I (Ks) cardiac potassium current. Nature 1996; 387:78-80.*
 - 15) Abbott GW, Sesti F, Splawski I, Buck ME, Lehmann MH, Timothy KW, Keating MT, Goldstein SA. *MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. Cell 1999;97:175-87.*
 - 16) Wei J, Wang DW, Alings M, Fish F, Wathen M, Roden DM, George AL Jr. *Congenital long-QT syndrome caused by a novel mutation in a conserved acidic domain of the cardiac Na⁺ channel. Circulation 1999;99:3165-71.*
 - 17) An RH, Wang XL, Kerem B, Benhorin J, Medina A, Goldmit M, Kass RS. *Novel LQT-3 mutation affects Na⁺ channel activity through interactions between alpha- and beta1-subunits. Circ Res 1998;83:141-6.*
 - 18) Schott JJ, Charpentier F, Peltier S, Foley P, Drouin E, Bouhour JB, Donnelly P, Vergnaud G, Bachner L, Moisan JP. *Mapping of a gene for long QT syndrome to chromosome 4q25-27. Am J Hum Genet 1995;57:1114-22.*
 - 19) Schulze-Bahr E, Wang Q, Wedekind H, Haverkamp W, Chen Q, Sun Y, Rubie C, Hordt M, Towbin JA, Borggrefe M, Asmann G, Qu X, Somberg JC, Breithardt G, Oberti C, Funke H. *KCNEL mutations cause jervell and Lange-Nielsen syndrome. Nat Genet 1997;17:267-8.*
 - 20) Zareba W, Moss AJ, Schwartz PJ, Vincent GM, Robinson JL, Priori SG, Benhorin J, Locati EH, Towbin JA, Keating MT, Lehmann MH, Hall WJ. *Influence of the genotype on the clinical course of the long-QT syndrome. N Engl J Med 1998;339:960-5.*
 - 21) Schwartz PJ. *The long QT syndrome. Curr Prob Cardiol 1997; 22:297-351.*
 - 22) Moss AJ, Zareba W, Hall WJ, Schwartz PJ, Crampton RS, Benhorin J, Vincent GM, Locati EH, Priori SG, Napolitano C, Medina A, Zhang L, Robinson JL, Timothy K, Towbin JA, Andrews ML. *Effectiveness and limitations of β -blocker therapy in congenital long QT syndrome. Circulation 2000; 101:616-23.*
 - 23) Hanck DA, Sheets MF. *Modification of inactivation in cardiac sodium channels: ionic current studies with Anthopleurin-A toxin. J Gen Physiol 1995;106:601-16.*
 - 24) Schwartz PJ, Priori SG, Locati EH, Napolitano C, Cantu F, Towbin JA, Keating MT, Hammoude H, Brown AM, Chen LS. *Long QT syndrome patients with mutation of the SCN5A and HERG genes have differential responses to Na⁺ channel blockade and to increases in heart rate: implications for genetic specific therapy. Circulation 1995;92:3381-6.*
 - 25) Shimizu W, Antzelevitch C. *Sodium channel block with mexiletine is effective in reducing dispersion of repolarization and preventing torsades de pointes in LQT2 and LQT3 models of the long-QT syndrome. Circulation 1997;96: 2038-47.*
 - 26) Garson A Jr, Dick M 2nd, Fournier A, Gillette PC, Hamilton R, Kugler JD, van Hare GF 3rd, Vetter V, Vick GW 3rd. *The long QT syndrome in children: an international study of 287 patients. Circulation 1993;87:1866-72.*
 - 27) Trippel DL, Parsons MK, Gillette PC. *Infants with long-QT syndrome and 2: 1 atrioventricular block. Am Heart J 1995; 130:1130-4.*
 - 28) Rosenbaum MB, Acunzo RS. *Pseudo 2: 1 atrioventricular block and T wave alternans in the long QT syndromes. J Am Coll Cardiol 1991;18:1363-6.*
 - 29) Scott WA, Dick M 2nd. *Two: one atrioventricular block in infants with congenital long QT syndrome. Am J Cardiol 1987; 60:1409-10.*
 - 30) Splawski I, Timothy K, Vincent GM, Atkinson DL, Keating MT. *Molecular basis of the long QT syndrome associated with deafness. N Engl J Med 1997;336:1562-7.*